Spots Global Cancer Trial Database for Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Official Title: A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Study ID: NCT03347292
Conditions
Study Description
Brief Summary: This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, status or response. The study will also investigate how the drugs behave in your body
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Hospital and Clinics, Los Angeles, California, United States
University of Florida Health Sciences Center, Gainesville, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Mount Sinai Medical Center, New York, New York, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
